Related Experiment Video
Updated: Jun 6, 2025
An Orthotopic Resectional Mouse Model of Pancreatic Cancer
Published on: September 24, 2020
A pooled analysis of pancreatic resection for metastatic renal cell carcinoma
Yanming Zhou1, Xiao Wang1, Shi Chen1
1Department of Surgery, First Affiliated Hospital of Xiamen University, Xiamen, China.
Background:
Pancreatic metastasis from renal cell carcinoma (PMRCC) is unusual and there is no consensus on its treatment. The present study aims to evaluate the clinical outcomes of surgical resection for PMRCC.
Methods:
PubMed and Web of Science were searched for Eligible studies from January 1980 to January 2024. Individual-patient data were pooled.
Results:
A total of 436 participants were identified. The morbidity and 90-day mortality were 38.1% and 3.4%, respectively. Post-pancreatectomy recurrence occurred in 44.1% of the patients. The overall median survival was 116 months, with a 3-, 5- and 10-year survival rate of 85.3%, 76.6%, and 46.5% respectively. On univariate analysis, repeat metastasectomy was associated with a significantly better prognosis (P =0.003).
Conclusion:
These data suggest that surgical resection is a safe and effective therapeutic option for PMRCC. Repeat metastasectomy is positively suggested for recurrent disease provided all metastases can be removed curatively.
Systematic Review Registration:
https://www.crd.york.ac.uk/prospero/, identifier CRD42024525218.
More Related Videos
12:34Robot-Assisted Radical Antegrade Modular Pancreatosplenectomy Including Resection and Reconstruction of the Spleno-Mesenteric Junction
Published on: January 3, 2020
10:38DIPLOMA Approach for Standardized Pathology Assessment of Distal Pancreatectomy Specimens
Published on: February 1, 2020